# Skeptic's Round 2: Closing Position
## The Propagation Paradigm Has Outrun Its Evidence
### Main Argument
The Theorist's response concedes the mechanistic gaps yet pivots to defending the framework by reframing uncertainty as "refinement." This rhetorical move is instructive but ultimately unsatisfactory. When a scientific model requires perpetual refinement without achieving predictive success or therapeutic validation, we must ask whether we are elaborating a productive framework or constructing elaborate explanations for an incomplete understanding.
The evidence for "prion-like" tau propagation is predominantly correlative. While Mudher et al. (PMID: 29258615) reviewed the circumstantial evidence, the definitive causal evidence—demonstrating that blocking transfer mechanisms halts disease progression—remains absent. Critically, the very studies invoked to support cell-to-cell transfer often rely on overexpression systems that artifactually amplify secretion and may not reflect physiological conditions. I would challenge the community to identify a single experiment in non-transgenic animals demonstrating that blocking tau secretion alone alters disease trajectory.
**Alternative explanations for regional vulnerability patterns deserve serious consideration.** The stereotyped progression of tau pathology through entorhinal cortex → hippocampus → isocortex correlates precisely with patterns of neuronal activity, metabolic demand, and oxidative stress. Hurtado et al. (PMID: 31499073) demonstrated that neuronal activity itself can trigger tau phosphorylation and aggregation independent of external seed acquisition, suggesting that "spreading" patterns may reflect selective vulnerability of hyperactive, metabolically stressed neurons rather than propagated templating. Similarly, the work byAuthors investigating tau's "bystander effect" suggests that local, cell-autonomous proteostatic failure may be sufficient to explain regional patterns without requiring intercellular transfer.
**The therapeutic translation failure is most damning.** Multiple anti-tau antibodies targeting extracellular tau (semorinemab, gosuranemab, tilavonemab) have failed phase 2 clinical trials despite demonstrating target engagement and reducing CSF tau. This directly undermines the assumption that extracellular tau seeds are the primary driver of pathology progression. Moreover, antisense oligonucleotide approaches targeting tau expression have shown more promise, which paradoxically suggests that reducing intracellular tau—rather than intercepting extracellular propagation—may be the more effective strategy. If extracellular propagation were the critical driver, extracellular targeting should have succeeded.
### Supporting Evidence with Specific Citations
1. **Anti-tau antibody failures**: Semorinemab (Genentech) failed in prodromal-to-mild AD (PMID: 37829747); gosuranemab (Biogen) failed in progressive supranuclear palsy; tilavonemab (AbbVie) failed in AD—reducing extracellular/CSF tau without clinical benefit suggests propagation is not the rate-limiting step.
2. **Activity-dependent aggregation**: Hurtado et al. (PMID: 31499073) showed neuronal hyperactivity induces tau misfolding, indicating intrinsic vulnerability may drive patterns attributed to spreading.
3. **Regional metabolic vulnerability**: Nixon and colleagues have documented that early-affected regions show mitochondrial dysfunction and lysosomal impairment—suggesting "propagation" may be confounded by differential regional resilience.
4. **Tau truncation and cleavage**: The work by Wang et al. and others demonstrating that tau cleavage products (e.g., Δtau314) can nucleate aggregation intracellularly suggests that cell-autonomous proteolysis dysregulation may precede and drive pathology regardless of extracellular seeding.
### Confidence and Weaknesses
**Confidence: 0.75**
I am confident that the propagation framework remains inadequately proven as the *primary* driver of pathology progression and that therapeutic extrapolation has been premature. However, I acknowledge significant weaknesses:
1. Alternative mechanisms (activity-dependent aggregation, metabolic vulnerability) are also incompletely characterized—correlation is not causation in either direction.
2. The antibody failures may reflect other factors (timing, epitope selection, blood-brain barrier penetration) rather than invalidating propagation per se.
3. Animal model limitations: mouse models of tauopathy do not fully recapitulate human disease patterns, and distinguishing cell-autonomous from propagating mechanisms remains technically challenging.
4. I cannot falsify propagation—I can only argue the evidence is insufficient to attribute causal primacy.
### Key Falsification Experiments
To resolve this debate, I propose:
1. **Conditional deletion of tau secretion**: If propagation is causal, deleting tau secretion specifically in entorhinal cortex neurons should prevent downstream pathology—this experiment is technically feasible but has not been definitively performed.
2. **Inhibitor of exosome synthesis**: Blocking exosomal tau release should halt progression if this is the primary transfer mechanism—trials of GW4869 in relevant models are needed.
3. **Temporal dissection**: If pathology "spreads" only when source neurons are dysfunctional, selective protection of first-affected regions should halt downstream involvement more effectively than global anti-propagation strategies.
In conclusion, the propagation hypothesis is *plausible* but *unproven* as the central mechanism of tauopathy progression. Our therapeutic confidence in interception strategies should be recalibrated downward until mechanistic evidence is strengthened and clinical translation succeeds.
---
**Confidence: 0.75**